2024
USPSTF Colorectal Cancer Screening Recommendation and Uptake for Individuals Aged 45 to 49 Years
Siddique S, Wang R, Yasin F, Gaddy J, Zhang L, Gross C, Ma X. USPSTF Colorectal Cancer Screening Recommendation and Uptake for Individuals Aged 45 to 49 Years. JAMA Network Open 2024, 7: e2436358. PMID: 39361285, PMCID: PMC11450516, DOI: 10.1001/jamanetworkopen.2024.36358.Peer-Reviewed Original ResearchConceptsUS Preventive Services Task ForceUS Preventive Services Task Force recommendationsColorectal cancer screening uptakeAverage-risk individualsScreening uptakeHigher socioeconomic statusSocioeconomic statusScreening recommendationsColorectal cancerColorectal cancer screening recommendationsPreventive Services Task ForceCohort studyCancer screening recommendationsScreening uptake ratesInterrupted time series analysisLow socioeconomic statusPrivate insurance beneficiariesScreening ratesSocioeconomic disparitiesRetrospective cohort studyMain OutcomesPotential disparitiesEvaluate changesClaims dataAbsolute changeCancer and incarceration: a call for action
Richman I, Gross C, Wang E. Cancer and incarceration: a call for action. The Lancet Oncology 2024, 25: 530-531. PMID: 38697151, DOI: 10.1016/s1470-2045(24)00201-8.Peer-Reviewed Original ResearchImmunotherapy utilization patterns in patients with advanced cancer and autoimmune disease
Li H, Huntington S, Gross C, Wang S. Immunotherapy utilization patterns in patients with advanced cancer and autoimmune disease. PLOS ONE 2024, 19: e0300789. PMID: 38625861, PMCID: PMC11020359, DOI: 10.1371/journal.pone.0300789.Peer-Reviewed Original ResearchConceptsAutoimmune diseasesImmunotherapy cycleFirst-lineNon-small cell lung cancerAdvanced cancerFirst-line immunotherapyOverall treatment toleranceCell lung cancerRenal cell carcinomaRetrospective cohort studyAssociated with lower oddsAdvanced melanomaCell carcinomaTreatment toleranceAbsolute contraindicationImmunotherapyConsensus guidelinesImprove cancer survivalLung cancerCohort studyClinical variablesCancer patientsAcademic centersPatientsIncidence rateArea Vulnerability and Disparities in Therapy for Patients With Metastatic Renal Cell Carcinoma
Rahman S, Long J, Westvold S, Leapman M, Spees L, Hurwitz M, McManus H, Gross C, Wheeler S, Dinan M. Area Vulnerability and Disparities in Therapy for Patients With Metastatic Renal Cell Carcinoma. JAMA Network Open 2024, 7: e248747. PMID: 38687479, PMCID: PMC11061765, DOI: 10.1001/jamanetworkopen.2024.8747.Peer-Reviewed Original ResearchConceptsMetastatic renal cell carcinomaArea-level measuresRenal cell carcinomaPatient-level factorsSystemic therapyEthnic disparitiesRelative risk ratiosSocially vulnerable areasCell carcinomaMeasures of social vulnerabilityMedicare beneficiariesCohort studyFee-for-service Medicare Parts AOdds ratioReceipt of systemic therapyLogistic regressionArea-level characteristicsAssociated with lack of treatmentNon-Hispanic blacksRetrospective cohort studyIndividual-level demographicsNon-Hispanic whitesAssociated with disparitiesUS Medicare beneficiariesMeasures of disadvantageEstimating Breast Cancer Overdiagnosis After Screening Mammography Among Older Women in the United States.
Richman I, Gross C. Estimating Breast Cancer Overdiagnosis After Screening Mammography Among Older Women in the United States. Annals Of Internal Medicine 2024, 177: 403-404. PMID: 38498894, DOI: 10.7326/l23-0485.Peer-Reviewed Original ResearchIntegrating 4 methods to evaluate physical function in patients with cancer (In4M): protocol for a prospective cohort study
Thanarajasingam G, Kluetz P, Bhatnagar V, Brown A, Cathcart-Rake E, Diamond M, Faust L, Fiero M, Huntington S, Jeffery M, Jones L, Noble B, Paludo J, Powers B, Ross J, Ritchie J, Ruddy K, Schellhorn S, Tarver M, Dueck A, Gross C. Integrating 4 methods to evaluate physical function in patients with cancer (In4M): protocol for a prospective cohort study. BMJ Open 2024, 14: e074030. PMID: 38199641, PMCID: PMC10806877, DOI: 10.1136/bmjopen-2023-074030.Peer-Reviewed Original ResearchConceptsPhysical function assessmentPhysical functionFunctional assessmentEvaluation of physical functionElectronic health record dataEvaluate physical functionHealth record dataSpanish-speaking patientsDigital health technologiesBreast cancerProspective cohort studyClinician-reported outcomesCancer clinical trialsClinical decision-makingStudy questionnairePatient-centred evaluationHealth technologiesMeasure symptomsOncology practiceCohort studyRecord dataPatient's impressionMayo ClinicEnglish-speakingWearable sensors
2023
FDA Regulations of AI-Driven Clinical Decision Support Devices Fall Short
Habib A, Gross C. FDA Regulations of AI-Driven Clinical Decision Support Devices Fall Short. JAMA Internal Medicine 2023, 183: 1401-1402. PMID: 37812411, DOI: 10.1001/jamainternmed.2023.5006.Peer-Reviewed Original ResearchScreening for Hypertensive Disorders of Pregnancy in the US—A New Hypertensive Urgency
Mitta S, Gross C, Simon M. Screening for Hypertensive Disorders of Pregnancy in the US—A New Hypertensive Urgency. JAMA Internal Medicine 2023, 183: 1185-1186. PMID: 37725383, DOI: 10.1001/jamainternmed.2023.4723.Peer-Reviewed Original ResearchImproving Support for Physician Scientists—Mind the (Funding) Gap
Kwan J, Gross C. Improving Support for Physician Scientists—Mind the (Funding) Gap. JAMA Network Open 2023, 6: e2332982. PMID: 37725379, DOI: 10.1001/jamanetworkopen.2023.32982.Peer-Reviewed Original ResearchHumansPhysiciansEstimating Breast Cancer Overdiagnosis After Screening Mammography Among Older Women in the United States.
Richman I, Long J, Soulos P, Wang S, Gross C. Estimating Breast Cancer Overdiagnosis After Screening Mammography Among Older Women in the United States. Annals Of Internal Medicine 2023, 176: 1172-1180. PMID: 37549389, PMCID: PMC10623662, DOI: 10.7326/m23-0133.Peer-Reviewed Original ResearchConceptsCumulative incidenceBreast cancerBreast cancer screeningUnscreened womenOlder womenCancer screeningBreast cancer-specific deathBreast cancer overdiagnosisService Medicare claimsRetrospective cohort studyCancer-specific deathBreast cancer deathsWomen 70 yearsHarms of overdiagnosisNational Cancer InstituteBreast cancer diagnosisCohort studyCancer overdiagnosisCancer deathSEER programMedicare claimsCancer InstituteOverdiagnosisGreater incidenceCancerNet Clinical Benefit as Measure of Treatment Benefit Among Older Adults With Advanced Incurable Non–Small Cell Lung Cancer—Reply
Voruganti T, Presley C, Gross C. Net Clinical Benefit as Measure of Treatment Benefit Among Older Adults With Advanced Incurable Non–Small Cell Lung Cancer—Reply. JAMA Oncology 2023, 9: 1154-1155. PMID: 37347467, DOI: 10.1001/jamaoncol.2023.1538.Peer-Reviewed Original ResearchRelative Burden of Cancer and Noncancer Mortality Among Long-Term Survivors of Breast, Prostate, and Colorectal Cancer in the US
Kc M, Fan J, Hyslop T, Hassan S, Cecchini M, Wang S, Silber A, Leapman M, Leeds I, Wheeler S, Spees L, Gross C, Lustberg M, Greenup R, Justice A, Oeffinger K, Dinan M. Relative Burden of Cancer and Noncancer Mortality Among Long-Term Survivors of Breast, Prostate, and Colorectal Cancer in the US. JAMA Network Open 2023, 6: e2323115. PMID: 37436746, PMCID: PMC10339147, DOI: 10.1001/jamanetworkopen.2023.23115.Peer-Reviewed Original ResearchConceptsLong-term survivorsCancer-specific mortalityColorectal cancerCancer cohortReceptor statusInitial diagnosisGleason scoreProstate cancerBreast cancerLong-term adult survivorsMedian cancer-specific survivalEnd Results cancer registryProstate-specific antigen levelRectal cancer cohortCancer-specific survivalStage III diseaseYear of diagnosisProgesterone receptor statusEstrogen receptor statusProportion of deathsSurvival time ratioEarly-stage cancerNononcologic outcomesIndex cancerLocalized diseaseEnd-of-Life Systemic Oncologic Treatment in the Immunotherapy Era: The Role of Race, Insurance, and Practice Setting
Canavan M, Wang X, Ascha M, Miksad R, Showalter T, Calip G, Gross C, Adelson K. End-of-Life Systemic Oncologic Treatment in the Immunotherapy Era: The Role of Race, Insurance, and Practice Setting. Journal Of Clinical Oncology 2023, 41: 4729-4738. PMID: 37339389, PMCID: PMC10602547, DOI: 10.1200/jco.22.02180.Peer-Reviewed Original ResearchConceptsSystemic treatmentEnd of lifeWhite patientsBlack patientsOdds ratioLarge real-world populationPractice settingsTreatment ratesPatient-level factorsEmergency department useIntensive care unitReal-world populationDay of deathImmunotherapy eraSystemic therapyOncologic treatmentCare unitDeidentified databaseDepartment usePatient raceInsurance typeMetastatic cancerDownstream careMedicaid patientsHigher oddsClinical Trial Diversity—Will We Know It When We See It?
Varma T, Gross C, Miller J. Clinical Trial Diversity—Will We Know It When We See It? JAMA Oncology 2023, 9: 765-767. PMID: 37022678, DOI: 10.1001/jamaoncol.2023.0143.Peer-Reviewed Original ResearchPrivate Equity in US Health Care—Now Cradle to Grave?
Crosson F, Ostrer I, Gross C. Private Equity in US Health Care—Now Cradle to Grave? JAMA Internal Medicine 2023, 183: 511-512. PMID: 37126342, DOI: 10.1001/jamainternmed.2023.0324.Peer-Reviewed Original ResearchCancer incidence among incarcerated and formerly incarcerated individuals: A statewide retrospective cohort study
Aminawung J, Soulos P, Oladeru O, Lin H, Gonsalves L, Puglisi L, Hassan S, Richman I, Wang E, Gross C. Cancer incidence among incarcerated and formerly incarcerated individuals: A statewide retrospective cohort study. Cancer Medicine 2023, 12: 15447-15454. PMID: 37248772, PMCID: PMC10417084, DOI: 10.1002/cam4.6162.Peer-Reviewed Original ResearchConceptsNon-Hispanic Black individualsScreen-detectable cancersStandardized incidence ratiosNon-Hispanic white individualsCancer incidenceGeneral populationStatewide retrospective cohort studyRetrospective cohort studyWhite individualsState tumor registryLower cancer incidenceBlack individualsHigher cancer incidenceIncarceration exposureCohort studyRetrospective cohortTumor RegistryIncidence ratiosIncarcerated individualsCancer screeningIncidence rateHigh incidenceConnecticut residentsEthnic strataIncidenceDisparities in immune and targeted therapy utilization for older US patients with metastatic renal cell carcinoma
Chow R, Long J, Hassan S, Wheeler S, Spees L, Leapman M, Hurwitz M, McManus H, Gross C, Dinan M. Disparities in immune and targeted therapy utilization for older US patients with metastatic renal cell carcinoma. JNCI Cancer Spectrum 2023, 7: pkad036. PMID: 37202354, PMCID: PMC10276895, DOI: 10.1093/jncics/pkad036.Peer-Reviewed Original ResearchConceptsOral anticancer agentsTherapy utilizationMedicare beneficiariesNon-Hispanic white raceMetastatic renal cell carcinomaNon-Hispanic black raceOlder US patientsUS Medicare beneficiariesRenal cell carcinomaLogistic regression modelsTherapy receiptMultivariable adjustmentSystemic therapyMale sexUS patientsCell carcinomaStudy criteriaBlack raceFemale sexPatient raceWhite raceImmunotherapyOutcomes persistSexPatientsParent Priorities in End-of-Life Care for Children With Cancer
Ananth P, Lindsay M, Mun S, McCollum S, Shabanova V, de Oliveira S, Pitafi S, Kirch R, Ma X, Gross C, Boyden J, Feudtner C, Wolfe J. Parent Priorities in End-of-Life Care for Children With Cancer. JAMA Network Open 2023, 6: e2313503. PMID: 37184834, PMCID: PMC10878399, DOI: 10.1001/jamanetworkopen.2023.13503.Peer-Reviewed Original ResearchPerceived appropriateness of assessing for health-related socioeconomic risks among adult patients with cancer
Vu M, Boyd K, De Marchis E, Garnache B, Gottlieb L, Gross C, Lee N, Lindau S, Mun S, Winslow V, Makelarski J. Perceived appropriateness of assessing for health-related socioeconomic risks among adult patients with cancer. Cancer Research Communications 2023, 3: 521-531. PMID: 37020993, PMCID: PMC10069714, DOI: 10.1158/2767-9764.crc-22-0283.Peer-Reviewed Original ResearchConceptsElectronic health recordsHealth care settingsAdult patientsCare settingsHealth care-related factorsCare-related factorsPerceptions of patientsAmerican Cancer SocietyFisher's exact testNational Cancer InstituteMost patientsOutpatient clinicCancer SocietySocioeconomic riskCancer InstitutePatientsExact testSelf-administered surveyEHR documentationSignificant associationSociodemographic characteristicsClinical settingCancerHealthcare settingsCancer treatmentHolding Medical Professional Society Scientific Meetings Only in States That Protect Abortion Rights—Clinical and Ethical Considerations
Gross C, Kraschel K, Emanuel E. Holding Medical Professional Society Scientific Meetings Only in States That Protect Abortion Rights—Clinical and Ethical Considerations. JAMA Internal Medicine 2023, 183: 283-284. PMID: 36848080, DOI: 10.1001/jamainternmed.2022.7073.Peer-Reviewed Original Research